Two Nuclear Localization Signals in USP1 Mediate Nuclear Import of the USP1/UAF1 Complex

9 p. : il.

Evidence for classification of c.1852_1853AA > GC in MLH1 as a neutral variant for Lynch syndrome

Background: Lynch syndrome (LS) is an autosomal dominant inherited cancer syndrome characterized by early onset cancers of the colorectum, endometrium and other tumours. A significant proportion of DNA variants in LS patients are unclassified. Reports on the pathogenicity of the c.1852_1853AA>GC (p.Lys618Ala) variant of the MLH1 gene are conflicting. In this study, we provide new evidence indicating that this variant has no significant implications for LS. Methods: The following approach was used to assess the clinical significance of the p.Lys618Ala variant: frequency in a control population, case-control comparison, co-occurrence of the p.Lys618Ala variant with a pathogenic mutation, co-segregation with the disease and microsatellite instability in tumours from carriers of the variant. We genotyped p.Lys618Ala in 1034 individuals (373 sporadic colorectal cancer [CRC] patients, 250 index subjects from families suspected of having LS [revised Bethesda guidelines] and 411 controls). Three well-characterized LS families that fulfilled the Amsterdam II Criteria and consisted of members with the p.Lys618Ala variant were included to assess co-occurrence and co-segregation. A subset of colorectal tumour DNA samples from 17 patients carrying the p.Lys618Ala variant was screened for microsatellite instability using five mononucleotide markers. Results: Twenty-seven individuals were heterozygous for the p.Lys618Ala variant; nine had sporadic CRC (2.41%), seven were suspected of having hereditary CRC (2.8%) and 11 were controls (2.68%). There were no significant associations in the case-control and case-case studies. The p.Lys618Ala variant was co-existent with pathogenic mutations in two unrelated LS families. In one family, the allele distribution of the pathogenic and unclassified variant was in trans, in the other family the pathogenic variant was detected in the MSH6 gene and only the deleterious variant co-segregated with the disease in both families. Only two positive cases of microsatellite instability (2/17, 11.8%) were detected in tumours from p.Lys618Ala carriers, indicating that this variant does not play a role in functional inactivation of MLH1 in CRC patients. Conclusions: The p.Lys618Ala variant should be considered a neutral variant for LS. These findings have implications for the clinical management of CRC probands and their relatives.

Comidas preparadas sin gluten : APPCC y planes de apoyo

La enfermedad celíaca es una intolerancia permanente al gluten, proteína que forma parte de algunos cereales como trigo,cebada, centeno, triticale, kamut, espelta y probablemente, avena. Esta proteína puede producir una lesión severa en la mucosa del intestino de los individuos celiacos que influye en la adecuada absorción de los nutrientes de los alimentos (proteínas, grasas, hidratos de carbono, sales minerales y vitaminas), provocando en ocasiones desequilibrios nutricionales. Los síntomas más habituales de la enfermedad son diarrea, malnutrición, distensión abdominal, rechazo alimentario, anemia, osteoporosis y en niños, retraso en el crecimiento. En España la prevalencia de la enfermedad celíaca es del 1% aunque hay que tener en cuenta que según estudios recientes el 75% de los celíacos están sin diagnosticar. En la actualidad el único tratamiento posible es mantener de por vida una alimentación libre de gluten. Cuando se sigue una dieta estricta sin gluten, las personas celíacas recuperan la estructura normal del intestino y desaparecen los síntomas descritos. El enfermo celíaco debe retirar de su dieta habitual los cereales que contienen gluten y todos los derivados de éstos. Algunos alimentos se identifican fácilmente, como por ejemplo, harinas, pastas alimenticias, productos de bollería y pastelería, panes, etc. Sin embargo, otros derivados forman parte de los alimentos como ingredientes y no se reconocen fácilmente. Dentro de este grupo se encuentran féculas, malta, sémolas, aditivos espesantes, etc.

Zeliakoentzako elikagaien elaborazioa. AKKPA eta laguntza-plangintza

Gaixotasun zeliakoa glutenarekiko intolerantzia jarraia da. Glutena gari, garagar, zekale, tritikale, kamut, espelta eta ziurrenik ere oloan dagoen proteina da. Glutenak zeliakoen heste-mukosan kalte larria eragin dezake eta ondorioz nutrienteen (poteina, gantz, karbohidrato, gatz mineral eta bitaminen) xurgapena muga dezake, kasu batzuetan desoreka nutrizionala eraginez. Gaixotasunaren sintoma ohikoenak beherakoa, malnutrizioa, sabeldistentsioa, elikagaien ukoa, anemia, osteoporosia eta, umeetan, hazkuntza-atzerapena dira. Espainian gaixotasun zeliakoaren prebalentzia %1 da, baina, hala ere, azken ikerketen arabera, zeliakoen %75 diagnostikatu gabe dago oraindik. Gaur egun, glutenik gabeko dieta jarraitzea da gaixotasun honek duen tratamendu bakarra. Glutenik gabeko dieta zorrotz bat jarraitzen denean, zeliakoek hestearen egitura normala berreskuratzen dute, eta aipatutako sintomak desagertzen dira. Pertsona zeliakoak glutena duten zerealak eta horien eratorriak baztertu behar ditu dietatik. Elikagai batzuk erraz identifikatzen dira: hala nola, irina, pasta, opilak, pastelak eta horien eratorriak, eta abar. Beste batzuk, ordea, elikagaiaren osagai direnez, ez dira elikagaitzat ezagutzen eta antzemateko zailagoak izaten dira. Talde horretan fekulak, malta, semolak, gehigarri loditzaileak, eta abar daude.

The MLH1 c.1852_1853delinsGC (p.K618A) Variant in Colorectal Cancer: Genetic Association Study in 18,723 Individuals

Colorectal cancer is one of the most frequent neoplasms and an important cause of mortality in the developed world. Mendelian syndromes account for about 5% of the total burden of CRC, being Lynch syndrome and familial adenomatous polyposis the most common forms. Lynch syndrome tumors develop mainly as a consequence of defective DNA mismatch repair associated with germline mutations in MLH1, MSH2, MSH6 and PMS2. A significant proportion of variants identified by screening these genes correspond to missense or noncoding changes without a clear pathogenic consequence, and they are designated as "variants of uncertain significance'', being the c.1852_1853delinsGC (p.K618A) variant in the MLH1 gene a clear example. The implication of this variant as a low-penetrance risk variant for CRC was assessed in the present study by performing a case-control study within a large cohort from the COGENT consortium-COST Action BM1206 including 18,723 individuals (8,055 colorectal cancer cases and 10,668 controls) and a case-only genotype-phenotype correlation with several clinical and pathological characteristics restricted to the Epicolon cohort. Our results showed no involvement of this variant as a low-penetrance variant for colorectal cancer genetic susceptibility and no association with any clinical and pathological characteristics including family history for this neoplasm or Lynch syndrome.

Pseudohypoparathyroidism Type Ib Associated with Novel Duplications in the GNAS Locus

Context Pseudohypoparathyroidism type 1b (PHP-Ib) is characterized by renal resistance to PTH (and, sometimes, a mild resistance to TSH) and absence of any features of Albright's hereditary osteodystrophy. Patients with PHP-Ib suffer of defects in the methylation pattern of the complex GNAS locus. PHP-Ib can be either sporadic or inherited in an autosomal dominant pattern. Whereas familial PHP-Ib is well characterized at the molecular level, the genetic cause of sporadic PHP-Ib cases remains elusive, although some molecular mechanisms have been associated with this subtype. Objective The aim of the study was to investigate the molecular and imprinting defects in the GNAS locus in two unrelated patients with PHP-Ib. Design We have analyzed the GNAS locus by direct sequencing, Methylation-Specific Multiplex Ligation-dependent Probe Amplification, microsatellites, Quantitative Multiplex PCR of Short Fluorescent fragments and array-Comparative Genomic Hybridization studies in order to characterize two unrelated families with clinical features of PHP-Ib. Results We identified two duplications in the GNAS region in two patients with PHP-Ib: one of them, comprising similar to 320 kb, occurred 'de novo' in the patient, whereas the other one, of similar to 179 kb in length, was inherited from the maternal allele. In both cases, no other known genetic cause was observed. Conclusion In this article, we describe the to-our-knowledge biggest duplications reported so far in the GNAS region. Both are associated to PHP-Ib, one of them occurring 'de novo' and the other one being maternally inherited.

Structure-function analysis of USP1: insights into the role of Ser313 phosphorylation site and the effect of cancer-associated mutations on autocleavage

Background: In complex with its cofactor UAF1, the USP1 deubiquitinase plays an important role in cellular processes related to cancer, including the response to DNA damage. The USP1/UAF1 complex is emerging as a novel target in cancer therapy, but several aspects of its function and regulation remain to be further clarified. These include the role of the serine 313 phosphorylation site, the relative contribution of different USP1 sequence motifs to UAF1 binding, and the potential effect of cancer-associated mutations on USP1 regulation by autocleavage. Methods: We have generated a large set of USP1 structural variants, including a catalytically inactive form (C90S), non-phosphorylatable (S313A) and phosphomimetic (S313D) mutants, deletion mutants lacking potential UAF1 binding sites, a mutant (GG/AA) unable to undergo autocleavage at the well-characterized G670/G671 diglycine motif, and four USP1 mutants identified in tumor samples that cluster around this cleavage site (G667A, L669P, K673T and A676T). Using cell-based assays, we have determined the ability of these mutants to bind UAF1, to reverse DNA damage-induced monoubiquitination of PCNA, and to undergo autocleavage. Results: A non-phosphorylatable S313A mutant of USP1 retained the ability to bind UAF1 and to reverse PCNA ubiquitination in cell-based assays. Regardless of the presence of a phosphomimetic S313D mutation, deletion of USP1 fragment 420-520 disrupted UAF1 binding, as determined using a nuclear relocation assay. The UAF1 binding site in a second UAF1-interacting DUB, USP46, was mapped to a region homologous to USP1(420-520). Regarding USP1 autocleavage, co-expression of the C90S and GG/AA mutants did not result in cleavage, while the cancer-associated mutation L669P was found to reduce cleavage efficiency. Conclusions: USP1 phosphorylation at S313 is not critical for PCNA deubiquitination, neither for binding to UAF1 in a cellular environment. In this context, USP1 amino acid motif 420-520 is necessary and sufficient for UAF1 binding. This motif, and a homologous amino acid segment that mediates USP46 binding to UAF1, map to the Fingers sub-domain of these DUBs. On the other hand, our results support the view that USP1 autocleavage may occur in cis, and can be altered by a cancer-associated mutation.

Alta precoz postparto. Evaluación de las complicaciones maternas y neonatales; repercusión en la ansiedad materna

246 p.